DeepScribe vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco ambient AI scribe using smartphone to listen to patient visits; generates structured EHR notes within minutes, customizable to each physician's documentation style.
About
DeepScribe is a San Francisco-based ambient AI medical scribe company that uses machine learning to listen to physician-patient conversations and automatically generate complete, structured clinical documentation without physician dictation or manual entry. The platform runs on a smartphone placed in the exam room, processes the conversation to identify medically relevant information, and presents a complete draft note in the EHR within minutes of the visit ending. DeepScribe differentiates through its customization capabilities — physicians can train the AI to match their personal documentation style, preferred note templates, and specialty-specific terminology, making the output immediately publishable with minimal editing. The company serves primary care, specialty, and urgent care physicians as well as telehealth providers. Founded in 2017, DeepScribe raised over $30M from investors including Kaiser Permanente Ventures, Greycroft, and SignalFire. The company has demonstrated significant time savings for clinicians and reductions in EHR-related stress. It competes with Suki AI, Nuance DAX, and Freed AI in the ambient medical scribe market.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.